Fortress Biotech, Inc.

Fortress Biotech is a biopharmaceutical company that develops and commercializes pharmaceutical products across dermatology and specialty therapeutic areas. The dermatology portfolio includes several marketed products: Emrosi for rosacea, Qbrexza for hyperhidrosis, Accutane for severe acne, Amzeeq and Zilxi for acne and rosacea respectively, Exelderm for fungal infections, Targadox for severe acne, and Luxamend for wound care. The company also markets medications such as intravenous Tramadol for post-operative pain management and develops products for rare and orphan indications.

The development pipeline spans multiple therapeutic areas including oncology, rare genetic diseases, and immunology. Notable clinical-stage candidates include CUTX-101 for Menkes disease, CAEL-101 for amyloid light chain amyloidosis, and several investigational compounds targeting glioblastoma, non-Hodgkin lymphoma, and non-small cell lung cancer. The company maintains preclinical programs in gene therapy and immunomodulation.

Based in Bay Harbor Islands, Florida, Fortress Biotech operates with approximately 101 full-time employees. The company is incorporated in Delaware and trades on the Nasdaq exchange. Revenue generation derives primarily from its commercialized dermatology and specialty pharmaceutical products, supplemented by development activities across its pipeline of candidates in various stages of clinical development.